Earnings call transcript: Sisram Medical H1 2026 profit falls as growth shifts to Asia

Sisram Medical reported H1 2026 revenue of $171.4M (+3.6% YoY) but adjusted net profit fell to $5.04M (from $12.0M), driven by heavier China injectable investment and the launch of its first pharmaceutical product. Gross margin declined 330 bps to 56.7% and shares fell 1.62% to $2.13, trading near the 52-week low (~$2.10). International revenue ex-North America rose 16.7% (APAC +19.1% YoY to 45% of total), with injectable revenue up 54.2% to $22.2M as DAXXIFY shipments surpassed 30,000 vials across 28 provinces. Management is confident H2 revenue will improve sequentially and YoY as profitability and cash flow recovery efforts ramp up.

Analysis

Sisram is transitioning from a single-engine device story to a mixed model where injectables and localization carry more value than near-term reported profit. The important second-order effect is that China manufacturing can compress lead times and reduce geopolitical friction, but the real economic payoff is 6-18 months out; near term, it just adds fixed-cost drag and keeps margins under pressure. That means the stock will likely trade on proof of repeat ordering and channel depth, not on headline revenue growth.

Competitive dynamics in botulinum toxin are the key risk. A crowded market usually pushes the middle tier into price competition first, while premium brands can defend ASPs only if clinicians see durable efficacy and better clinic economics. If DAXXIFY fails to convert coverage into repeat utilization, the injectables thesis becomes a marketing story rather than a margin driver; that would also spill over into the broader ecosystem pitch and slow cross-sell into devices and skincare.

The contrarian view is that the market may be underestimating how much optionality is embedded in an integrated platform with APAC localization and a China-first growth plan. But the more immediate risk is that investors are correctly discounting execution: North America weakness, margin dilution, and regulatory lag on new products can keep the multiple pinned until there is visible operating leverage. Falsifiers are straightforward: a second half revenue inflection without gross margin recovery, or any sign that China injectables remain coverage-heavy but low-repurchase.

Key Decisions for Investors

• 1696.HK: Initiate only a starter long on a retest of HK$2.10-2.20, sized for 6-9 months. Upside is to HK$3.20-3.50 if second-half revenue accelerates and gross margin reclaims ~58%; stop if HK$2.00 breaks or the next print shows no margin recovery.
• 1696.HK: Add only after two confirmations — DAXXIFY repeat ordering remains 'healthy' in the next update and the Profhilo China filing is submitted in H2 2026. If either slips, cut exposure by 50% because the platform thesis is then ahead of the data.
• Avoid shorting the stock into weakness at current levels; the risk/reward is poor near the 52-week low. Consider a tactical short only after a >20% relief rally without evidence of gross-margin stabilization, using the next earnings update as the catalyst window.